Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: May 22, 2025

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

Testing Meningiomas With Methylation Arrays: Insights and Recommendations From a Large Single-Centre Study.

Fernanda Ruiz¹, Rossella Rispoli^1,2, Zane Jaunmuktane^1,3

¹Division of Neuropathology, the National Hospital for Neurology and Neurosurgery, University College NHS Foundation Trust, London, UK.

Neuropathology and Applied Neurobiology

|May 13, 2025

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Interlaboratory performance testing on EPIC v2.0 CNS tumor profiling demonstrates high reproducibility of tumor classification but reveals the need for harmonized copy number variation reporting.

Brain pathology (Zurich, Switzerland)·2026

Same author

Distinct molecular subgroups in pediatric and young-onset meningiomas require age-adapted risk stratification.

Nature communications·2026

Same author

Performance of Alzheimer Disease Plasma Biomarkers in Patients With Prion Diseases.

Neurology·2026

Same author

AI-based selection of tumor regions for genomic profiling in neuropathology.

Neuro-oncology advances·2026

Same author

Repeat expansions in Parkinson's disease and parkinsonism across ancestries: insights from a global genetic cohort.

medRxiv : the preprint server for health sciences·2026

Same author

IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.

Nature cancer·2026

Molecular testing helps predict meningioma recurrence risk. Grade 2 and 3 meningiomas require priority for methylation profiling, while some Grade 1 cases may also benefit.

Area of Science:

Neuropathology
Oncology
Genomics

Background:

Meningiomas are common primary central nervous system (CNS) tumors.
Current histological grading (WHO) has limitations in predicting recurrence risk.
Integrated molecular testing (methylation class, copy number profile) improves risk stratification.

Purpose of the Study:

To guide prioritization for molecular testing in meningiomas.
To understand how WHO grades correlate with molecular risk strata.
To assess the financial viability of applying prediction algorithms broadly.

Main Methods:

Retrospective analysis of over 1000 meningiomas.
Utilized methylation array analysis.
Focused on a single-center dataset.

Keywords:

CNS WHO grading meningioma methylation array model score prognostication

More Related Videos

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis

Published on: May 31, 2020

Methyl-binding DNA capture Sequencing for Patient Tissues

Methyl-binding DNA capture Sequencing for Patient Tissues

Published on: October 31, 2016

Related Experiment Videos

Last Updated: May 22, 2025

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis

Published on: May 31, 2020

Methyl-binding DNA capture Sequencing for Patient Tissues

Methyl-binding DNA capture Sequencing for Patient Tissues

Published on: October 31, 2016

Main Results:

~90% of Grade 1 meningiomas were classified as 'benign' and low-risk.
Grade 2 meningiomas showed varied risk stratification: 39% low, 46% intermediate, 15% high.
Grade 3 meningiomas were predominantly high-risk (74%) or intermediate-risk (26%).

Conclusions:

Prioritize Grade 2 and 3 meningiomas for methylation profiling.
Consider molecular analysis for a subset of Grade 1 meningiomas with potential for increased recurrence risk.
Further research is needed for Grade 1 meningiomas with predicted higher recurrence risk.